Molecular targeted therapy of non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2018.01.009
- VernacularTitle:非小细胞肺癌的分子靶向治疗
- Author:
Zhaodi NAN
1
;
Shaoshui CHEN
Author Information
1. 256600,滨州医学院附属医院肿瘤科
- Keywords:
Carcinoma,non-small-cell lung;
Immunotoxins;
Therapeutic uses
- From:
Journal of International Oncology
2018;45(1):39-43
- CountryChina
- Language:Chinese
-
Abstract:
At present,the treatment of non-small cell lung cancer (NSCLC) has entered the era of targeted therapy,and small molecule tyrosine kinase inhibitors are typical representatives,which have clear molecular targets and remarkable effects.But many patients without mutations are not able to benefit from them.Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment.Inhibitors such as programmed cell death-1 and programmed cell death-ligand 1 have shown great applied potential in a series of clinical trials of NSCLC.
